To update the guidelines regarding vitamin D status in respiratory distress syndrome, we reviewed recent human and animal studies on the benefits of vitamin D in respiratory distress. We searched PubMed and ProQuest for studies on the use of vitamin D from 2009 to 2017. e common parameters in these studies included the use of lung tissue, phospholipids, blood, and plasma to assess the effects of vitamin D on respiratory syndrome. e metabolized form of vitamin D used in these studies was 1,25(OH) 2 D 3 in animal studies and 25(OH)D in human studies. Vitamin D supplementation decreases the risk of respiratory distress syndrome, improves the quality of life, and is relatively effective and safe for preterm neonates as well as during lung maturation. However, although vitamin D supplementation may offer benefits for respiratory distress syndrome, the optimal dosing strategies for specific types of risk factors in the lungs must be clarified to confirm the therapeutic efficacy.
Introduction
Vitamin D has been reported to play roles in musculoskeletal function, regulation of hormone secretion, immune system function, and regulation of cell proliferation and differentiation [1] . In its classic function, small doses of vitamin D are necessary to regulate the calcium and phosphate balance, and it also plays an anti-inflammatory role. In addition, vitamin D receptor interacts with many chromosomes to effect different organs [2] . Vitamin D is naturally obtained from sunlight and synthesized by the body.
More recently, vitamin D has been shown to assist in lung maturation. e correlation between lung maturation and vitamin D is explained by the mechanism of phospholipid (surfactant) production and secretion on the surface of alveolar type II (ATII) cells [3] . e concentration of surfactant in ATII cells is associated with pregnancy gestation; therefore, the maturation of lung surfactant also progresses with pregnancy gestation.
Knowledge of the role of vitamin D has expanded over many years, and research has been conducted to determine the association between vitamin D status and health problems. American adult populations over the last 20 years have obtained only an estimated 40% of the necessary vitamin D levels. Vitamin D deficiency can increase the risk of many other diseases of the musculoskeletal, cardiovascular, and respiratory systems, as well as cancer [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . However, more evidence is necessary to determine the association with these diseases, particularly for respiratory distress syndrome.
In 2015, Lykkedegn et al. reported evidence on the benefits of vitamin D for respiratory distress syndrome treatment and prevention. ey showed substantial evidence of multiple physiological actions through which vitamin D stimulates maturation of the fetal lung, including ATII cell maturation and alveolarization. eir results supported the hypothesis that vitamin D deficiency or insufficiency is a frequent, modifiable risk factor for respiratory distress syndrome [3] .
e recommended levels of vitamin D are divided into a few classifications as shown in Table 1 . e recommendations for vitamin D levels require more evidence and research, particularly for the prevention or treatment of respiratory distress syndrome. e classifications from the Institute of Medicine [14] , the Endocrine Society [15] , and the Pediatric Endocrine Society [16] are not the final official recommendations. erefore, more studies are necessary to demonstrate the correlation between vitamin D deficiency and respiratory distress syndrome.
Respiratory distress syndrome is known to be associated with the hyaline membrane. is disease can worsen and lead to atelectasis, hypoxia, hypercarbia, tachypnea, retraction, asthma, and pneumonia. For almost three decades, the primary treatment of this disease has been corticosteroids and exogenous surfactants, which come with many problems such as high cost and side effects, especially in children. Respiratory distress syndrome is also triggered by physical, chemical, and hormonal systems that influence the maturation and production of lungs and the secretion of other components such as phospholipids. Generally, respiratory distress syndrome occurs in premature babies during normal conditions or operation procedures [17] .
Phospholipids can spread to other locations after entering the alveolar system, thus reducing the concentration of lung surfactant. e main cause of respiratory distress syndrome is the lack of surfactant in the lungs. is surfactant is primarily composed of phospholipids and is responsible for maintaining the surface tension of the lungs. Immaturity in the lung structure, coupled with low amounts of surfactant, is known to reduce the compliance and increase the propensity of other complications, such as atelectasis. Atelectasis induces slight ventilation of the lungs and prompts the mismatch of (V/Q), as well as alveolar hypoventilation such as hypercarbia and hypoxemia. Subsequent hypoxemia and hypoperfusion disrupt O 2 circulation, leading to anaerobic metabolism and lactic acidosis. is condition impacts acidosis hypoxemia and increases pulmonary vasoconstriction. Other complications such as volutrauma, and high FIO 2 may stimulate chemokines and cytokine inflammatory mechanisms, inducing injury to the epithelial cells. Epithelial cell injury reduces lung surfactant production and increases the permeability of the membrane, which can develop into complications such as respiratory distress syndrome [18] .
Methodology
Our review is based on the literature obtained from the PubMed and ProQuest databases using the keywords "Vitamin D deficiency" and "Respiratory Distress Syndrome." e specific keywords related to the pathophysiology of respiratory distress syndrome used were "Surfactant deficiency," "atelectasis," "cytokines," and "pulmonary vasoconstriction." e following exclusion criteria were applied: reviews, opinions or commentaries, non-English language, and unrelated topics such as the lack of vitamin D data, surfactant deficiency, and chronic respiratory syndrome disease. e flowchart of the literature search can be seen in Figure 1 .
Animal Studies on the Roles of Vitamin D in Lung Development
Twelve animal studies on the roles of vitamin D in lung development were included in the current study (Table 2) [31, 32] .
In the same year, research from Marin et al. confirmed that the vitamin D metabolite (1,25(OH) 2 D 3 ) increased the presence of phospholipids, which are a primary component of surfactants. ey found that dexamethasone could also increase the presence of phospholipids, but the mechanism was unclear. Conversely, the secosteroid vitamin D has been shown to have the same mechanism as dexamethasone when administered for respiratory distress syndrome treatment [33] .
As the mechanism of vitamin D in ATII cells remains unclear, in 1993, Edelson et al. attempted to answer this question by using an animal model to determine the role of 1,25(OH) 2 D 3 in ATII cells.
e results showed that 1,25 (OH) 2 D 3 had the potential to bind in ATII cells, but only in neonatal and adult epithelial cells [34] . Similarly, in 2009, Sakurai et al. explored this question through a biomolecular approach. ey evaluated cell proliferation, fibroblast apoptosis, alveolar epithelial-mesenchymal interactions, and morphology with Sprague-Dawley rat models using various doses (1,25D (10 ng/kg body weight) or 3-epi-1,25D (50 ng/kg body weight) administered once daily intraperitoneally, starting from the day of delivery (day 0). e data showed that supplementation of vitamin D in its active metabolite form could increase the synthesis of surfactants during the maturation of the lungs [19] .
In 2011, Zosky et al. employed another approach to investigate the mechanism of vitamin D with various intervention doses in newborn BALB/c mice with the aim to determine the development of lung volume (TGV), lung mechanics, and lung structure. In this study, they found a correlation between vitamin D deficiency and lung maturation, supporting the association of vitamin D status with lung disease [20] . In 2014, Yurt et al. furthered Zosky's work on lung morphology, phospholipid synthesis, alveolar 2
Advances in Pharmacological Sciences epithelial-mesenchymal interactions, and lung function. ey used Sprague-Dawley rats to determine the optimal time for vitamin D supplementation during pregnancy. e results showed that vitamin D deficiency influences alveolar cells and airway contractility. Vitamin D supplementation improved lung function at a dose of 500 IU/kg in a rat model [21] .
Vitamin D deficiency in lung injury was also reported to exaggerated alveolar inflammation, epithelial damage, and hypoxia of lipopolysaccharide-(LPS-) induced acute lung injury [22] . Furthermore, it was also found that the lack of vitamin D receptor in the pulmonary epithelial barrier will lead to a more severe LPS-induced lung injury [23] . e protective role of vitamin D in LPS-induced lung injury was then explained by report of Xu et al. to be through regulation of the balance between the expression of members of the renin-angiotensin system [24] . Conflicting result, however, also found by Klaff et al. that reported LPS-induced lung injury was independent of serum vitamin D concentration [25] .
To confirm the influence of modified doses of vitamin D, Mandell et al. conducted another study in 2014 using Sprague-Dawley rats fed a diet including vitamin D supplements. e study evaluated the optimal time and showed that early treatment was better because it could improve alveolar maturation by 14% in 14 days after birth [26] . Similar to the studies on vitamin D deficiency, in 2016, Lykkedegn et al. evaluated vitamin D depletion and the development of lung surfactant in female Sprague-Dawley rats. e animal models were used to compare two groups with different doses: a diet group (n � 18) (<5 IU/kg cholecalciferol) and a control diet group (n � 16) (1500 IU/kg cholecalciferol).
is study confirmed the association between vitamin D depletion and respiratory insufficiency in preterm neonates [27] .
In 2015, Chen et al. confirmed the association between high vitamin D levels in the form of 1,25(OH)2D3 on interleukin (IL)-4, IL-12, IL-13, interferon-γ, and ovalbumin-JAK1/p-STAT6/SOCS5. e results showed that the level of vitamin D was related to many pathological aspects of respiratory distress at the molecular level because it influenced the amount of specific proteins in ATII cells [28] . In another study on the molecular level, particularly regarding protein expression and vitamin D deficiency, Chen et al. identified the lung development pathways that are sensitive to vitamin D deficiency using female BALB/c mouse models in 2016.
e study involved control mice that were vitamin D-deficient (no vitamin D3 intake). e treatment mice were fed replete (2195 IU/kg vitamin D3) diets (Specialty Feeds, Glen Forrest, Western Australia) for at least 5 weeks before mating with the replete male mice. e results showed that there was no difference in protein expression in the offspring [29] . To investigate the optimal dosing method, Taylor Advances in Pharmacological Sciencessynthesis, and lung morphology. However, the data indicated insignificant increases in 25(OH) 2 D 3 [30] .
Clinical Studies on Vitamin D as a Risk Factor for Respiratory Distress Syndrome
Four studies on the roles of vitamin D as a risk factor for respiratory distress syndrome are included in the current review (Table 3) contributed to the prevention of complications in preterm babies with respiratory distress [38] . e level of vitamin D in preterm babies with respiratory distress was evaluated by Ataseven et al. in 2013. Peripheral blood samples were obtained from 150 preterm newborns, born after 29-35 weeks of gestation, to investigate whether 25(OH)D deficiency is a risk factor for respiratory distress syndrome. In this study, no correlation between gestational age and vitamin D levels was found. However, the incidence of respiratory distress syndrome was significantly higher in preterm babies in severe condition (28%). High levels of 2015 . ey showed that vitamin D deficiency is a common problem, particularly in patients with respiratory distress syndrome. In vitro studies have shown that vitamin D deficiency leads to inflammation in epithelial cells and affects more than 600 genes. ese in vivo and in vitro studies demonstrate that vitamin D levels influence the risk of acute respiratory distress syndrome. However, they suggest that other risk factors related to this situation should be examined [22] .
e association between vitamin D levels and respiratory distress syndrome was also assessed by Barnett et al. in 2013. e authors showed that the level of 25-OHD measured early after admission to intensive care was not associated with the development of acute lung injury and hospital or one-year mortality in critically ill patients with sepsis. However, lower 25-OHD levels were associated with higher one-year mortality in patients with severe trauma [36] .
Conclusions and Future Research
is review paper summarizes 11 studies on vitamin D and risk factors conducted between 2009 and 2016. e studies included animal and human patients and assessed vitamin D status and its many associations with ATII cells. is review highlights the sparse data on many factors, particularly doses. e tables presented above show research in animals with many different contexts, but further research is necessary both in humans and in animals. Vitamin D deficiency affects lung structure and function by lowering oxygenation and reducing the survival time in preterm neonates. In addition, vitamin D can effectively improve lung maturation, lung volume, and ATII cells; it can also induce respiratory distress syndrome in preterm neonates. In future studies, the optimal time periods for vitamin D supplementation should be further explored to determine the relationship with prophylaxis or treatment.
e results of our summary suggest the benefits of vitamin D supplementation at doses of 250-1000 IU/kg in animals. More evidence-based information and additional studies are necessary to confirm the therapeutic benefits of vitamin D supplementation in humans and animals and to describe the molecular pathways of these mechanisms. Furthermore, more evidence is necessary to determine the best therapeutic use of vitamin D, particularly regarding doses, optimal time, protein expression, and toxicity in humans and animals. Additionally, the optimal dosing strategies for specific types of risk factors in the lungs must be clarified to confirm the therapeutic efficacy before it can be recommended for broad clinical use.
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